Clinical Trial Update: Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL) [Phase 1]

View source ↗

Summary

A Phase 1 trial is evaluating adding loncastuximab and roflumilast to the Rituximab-CHOP regimen for adults with naïve high-risk Diffuse Large B-cell Lymphoma; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Loncastuximab (loncastuximab tesirin)
• Rituximab (rituximab)
• Roflumilast (roflumilast)

Snippet

Sponsor: The University of Texas Health Science Center at San Antonio | Conditions: Diffuse Large B-cell Lymphoma | Phase 1 | Status: RECRUITING